Endocrine Abstracts

Denosumab is a monoclonal antibody used in the treatment of osteoporosis to prevent bony injuries by increasing bone density. It does so by binding to RANK-L, which is then unable to activate RANK, thereby preventing osteoclast maturation and viability. Although rare, the effect of denosumab can interfere with the body’s calcium homeostasis and lead to a hypocalcemic state. We present a case where a post-menopausal female developed severe, symptomatic hypocalcemia from a...